Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

405 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Direct actions of GLP-1 analogues on AMP-activated protein kinase activity are distinct from cyclic AMP accumulation.
Samson SL, Bajaj M. Samson SL, et al. Among authors: bajaj m. J Hepatol. 2013 Mar;58(3):634-5. doi: 10.1016/j.jhep.2012.10.032. Epub 2012 Nov 14. J Hepatol. 2013. PMID: 23159768 No abstract available.
Myocardial protection against ischemia-reperfusion injury by GLP-1: molecular mechanisms.
Birnbaum Y, Ye Y, Bajaj M. Birnbaum Y, et al. Among authors: bajaj m. Metab Syndr Relat Disord. 2012 Dec;10(6):387-90. doi: 10.1089/met.2012.0095. Epub 2012 Sep 17. Metab Syndr Relat Disord. 2012. PMID: 22985024 Review. No abstract available.
Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury.
Qian J, Chen H, Birnbaum Y, Nanhwan MK, Bajaj M, Ye Y. Qian J, et al. Among authors: bajaj m. Cardiovasc Drugs Ther. 2016 Apr;30(2):129-41. doi: 10.1007/s10557-016-6650-9. Cardiovasc Drugs Ther. 2016. PMID: 26861490
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Birnbaum Y, Bajaj M, Yang HC, Ye Y. Birnbaum Y, et al. Among authors: bajaj m. Cardiovasc Drugs Ther. 2018 Apr;32(2):135-145. doi: 10.1007/s10557-018-6778-x. Cardiovasc Drugs Ther. 2018. PMID: 29508169
GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials.
Jia X, Alam M, Ye Y, Bajaj M, Birnbaum Y. Jia X, et al. Among authors: bajaj m. Cardiovasc Drugs Ther. 2018 Feb;32(1):65-72. doi: 10.1007/s10557-018-6773-2. Cardiovasc Drugs Ther. 2018. PMID: 29445896
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. Ye Y, et al. Among authors: bajaj m. Cardiovasc Drugs Ther. 2017 Apr;31(2):119-132. doi: 10.1007/s10557-017-6725-2. Cardiovasc Drugs Ther. 2017. PMID: 28447181
Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation.
Ye Y, Jia X, Bajaj M, Birnbaum Y. Ye Y, et al. Among authors: bajaj m. Cardiovasc Drugs Ther. 2018 Dec;32(6):553-558. doi: 10.1007/s10557-018-6837-3. Cardiovasc Drugs Ther. 2018. PMID: 30367338
Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.
Ye Y, Qian J, Castillo AC, Ling S, Ye H, Perez-Polo JR, Bajaj M, Birnbaum Y. Ye Y, et al. Among authors: bajaj m. Am J Physiol Heart Circ Physiol. 2013 Jan 1;304(1):H131-41. doi: 10.1152/ajpheart.00609.2012. Epub 2012 Oct 26. Am J Physiol Heart Circ Physiol. 2013. PMID: 23103492
Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.
Briones M, Bajaj M. Briones M, et al. Among authors: bajaj m. Expert Opin Pharmacother. 2006 Jun;7(8):1055-64. doi: 10.1517/14656566.7.8.1055. Expert Opin Pharmacother. 2006. PMID: 16722815 Review.
Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia.
Chen Y, Chen H, Birnbaum Y, Nanhwan MK, Bajaj M, Ye Y, Qian J. Chen Y, et al. Among authors: bajaj m. Diab Vasc Dis Res. 2017 Mar;14(2):152-162. doi: 10.1177/1479164116679081. Epub 2017 Jan 23. Diab Vasc Dis Res. 2017. PMID: 28111985 Free PMC article.
405 results
Jump to page
Feedback